Inhibition of influenza a virus infection by natural isoquinoline alkaloid neferine targeting virus nucleoprotein.

BACKGROUND

Influenza A virus (IAV) poses a serious threat to human health, and the increasing problem of drug resistance, along with the emergence of highly pathogenic strains, makes the development of new antiviral drugs urgent. Neferine, a dibenzylisoquinoline alkaloid derived from Nelumbo nucifera Gaertn plant, possesses multiple pharmacological activities, including anti-tumor, cardiovascular protection, neuroprotection, and anti-inflammatory effects.

PURPOSE: In this study, the anti-influenza A virus (IAV) activities and mechanisms of Neferine in vitro and in vivo were investigated in order to provide reference for the development of novel plant-derived anti-IAV drugs.

METHODS

The antiviral activity of Neferine against IAV in vitro was evaluated using plaque reduction assay, RT-PCR, and western blot assay. The anti-IAV mechanisms of Neferine's were determined through mini-genome assay, DARTS assay, and SPR analysis. The in vivo anti-IAV effects of Neferine were investigated using a mouse pneumonia model combined with HE staining.

RESULTS

Neferine exhibits broad-spectrum and highly effective antiviral activity against IAV at the cellular level. Neferine can "trap" the influenza virus in early endosomes, preventing its transport from early to late endosomes. Neferine primarily targets the NP protein of IAV to block its nuclear import and oligomerization. Neferine may bind to the Glu339 site of NP, which is a highly conserved. Additionally, it demonstrates significant protective effects against IAV infection in mice, notably improving the survival rates and accelerating weight recovery.

CONCLUSION

Neferine exhibits significant anti-IAV activity both in vitro and in vivo. It inhibits IAV infection by blocking the transport of IAV from early to late endosomes and inhibiting the functions of nucleoprotein (NP). These findings provide a substantial theoretical and experimental foundation for the development of Neferine as a novel anti-IAV agent.